Dr. Jost Reinhard will take over as head of Bayer AG’s Investor Relations department effective October 1, 2023. The 51-year-old is currently responsible for Bayer’s Cell and Gene Therapy unit in the United States. Reinhard will report directly to CEO Bill Anderson in his new capacity. He succeeds Oliver Maier (57), who has headed up the Investor Relations department since March 2017 and as of October 1 will continue to work for Bayer in a senior advisory role.
Jost Reinhard was born in Traben-Trarbach, Germany, on April 28, 1972. He studied pharmacy in Bonn, Germany, and Dijon, France, and earned his doctorate in molecular toxicology and medicinal chemistry from the German Cancer Research Center in Heidelberg. Reinhard began his career at the company in 2001, in the Research & Development department of the Berlin-based company Schering AG, which was acquired by Bayer in 2006. After working in a variety of positions in areas such as Investor Relations and Corporate Communications, from 2010 onward Reinhard was appointed to commercial leadership roles with increasing responsibility in Australia, Poland and France. In 2021, he relocated to the United States to head the Cell and Gene Therapy unit, a key area of innovation for Bayer.